Banner

No attention-boosting drugs for healthy kids, doctors urge

Doctors at Yale School of Medicine and the American Academy of Neurology (AAN) have called upon their fellow physicians to limit or end the practice of prescribing memory-enhancing drugs to healthy children whose brains are still developing. Their position statement is published in the March online issue of the journal Neurology, the medical journal of the AAN.

The statement was written to address the growing trend in which teens use "study drugs" before tests and parents request attention deficit hyperactivity disorder (ADHD) drugs for children who don't meet the criteria for the disorder. The AAN spent several years analyzing all of the available research and ethical issues to develop this official position statement on the topic.

"Doctors caring for children and teens have a professional obligation to always protect the best interests of the child, to protect vulnerable populations, and to prevent the misuse of medication," said first author of the statement, William Graf, M.D., professor of pediatrics and neurology at Yale School of Medicine. "The practice of prescribing these drugs, called neuroenhancements, for healthy students is not justifiable."

Graf and a group of child neurologists provide evidence that points to dozens of ethical, legal, social, and developmental reasons why prescribing mind-enhancing drugs, such as those used to treat ADHD, for healthy people is viewed differently in children and adolescents than it would be in functional, independent adults with full decision-making capacities.

Some of the reasons not to prescribe neuroenhancements include: the child's best interest; the long-term health and safety of neuroenhancements, which has not been studied in children; kids and teens may lack complete decision-making capacities while their judgments and cognitive abilities are still developing; maintaining doctor-patient trust; and the risks of over-medication and dependency.

"A physician should talk to the child about the request, as it may reflect other medical, social, or psychological motivations such as anxiety, depression, or insomnia," said Graf, who notes that there are alternatives to neuroenhancements available, including maintaining good sleep, nutrition, study habits, and exercise regimens.

Other authors on the position statement include Saskia K. Nagel, Leon G. Epstein, M.D., Geoffrey Miller, M.D., Ruth Nass, M.D., and Dan Larriviere, M.D.

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Banner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

News in Pictures

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/9445461331.jpg

Abbott Launches New Psoriasisanswers.com Web site

August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/399322AstraZeneca_Headquarters.jpg

AstraZeneca Headquarters, London

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/280148roche_basel.jpg

Site Roche Basel

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/390839Gehry_Novartis.jpg

Gehry building, Novartis headquarters in Basel, Switzerland

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/240209GSK_Corporate.jpg

GSK Corporate HQ

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/200324sanofi_avenits.jpg

Sanofi-aventis Group head office

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/964792Boehringer_Ingelheim_Center.jpg

Boehringer Ingelheim Center, Ingelheim, Germany

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/164840Novo_Nordisk.jpg

Novo Nordisk's corporate headquarters in Bagsværd, Denmark

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more

Be on top of World Pharma News
Want to place your Ads or News at the top of World Pharma News? Contact us now!